Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA
I'm PortAI, I can summarize articles.
Jiuzhou Pharma's subsidiary, Reibo Suzhou, underwent a cGMP on-site inspection by the U.S. FDA from May 19 to 22, 2025, and passed the inspection. This inspection covered six major systems, including quality systems, materials, and production, indicating that Reibo Suzhou meets FDA requirements, providing assurance for the company's expansion into international markets and positively impacting the global regulatory market. The company has established a cGMP quality management system that meets global standards, enhancing its overall competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments